I am wondering if the 7 day lead in dosage of bisantrene planned for the P2 trial will not only act as a way to gather data on FTO inhibition, but will also increase the chances of seeing a cardio protective effect.
The reasoning is that there are multiple MOAs for doxorubicin as an anticancer agent (one reason why it's particularly effective) and there are multiple MOAs for it's cardiotoxicity. Therefore if bisantrene is cardio protective, it will have to somehow stop doxorubicin from getting into heart cells and doing it's damage. If administered by itself first, could bisantrene "saturate" heart cells and prevent the doxorubicin damage?
Interested to hear your thoughts.
Happy New Year everyone.
I am wondering if the 7 day lead in dosage of bisantrene planned...
-
- There are more pages in this discussion • 532 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.81 |
Change
-0.010(0.55%) |
Mkt cap ! $307.3M | |||
| Open | High | Low | Value | Volume |
| $1.83 | $1.84 | $1.78 | $271.2K | 150.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.81 | 349 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |